CETP rs9923854: Longevity, HDL, and Cognitive Aging
rs9923854 is a single nucleotide polymorphism located in the promoter region of the cholesteryl ester transfer protein (CETP) gene on chromosome 16. Population studies have linked this regulatory variant to differences in plasma HDL cholesterol concentrations, preserved late-life cognitive function, and exceptional human longevity. However, overall evidence remains limited and is characterized by modest effect sizes and variation across ancestries.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| CC | The homozygous reference genotype is common across most global populations. In observational studies, individuals with this genotype typically display standard baseline CETP promoter activity and average population-level HDL cholesterol profiles. | Informational |
| CT | Carrying one copy of the alternative T allele is associated with modest differences in CETP promoter expression. Cohort studies of European ancestry observe slight statistical increases in circulating HDL cholesterol and subtle shifts toward favorable longevity metrics. | Favorable |
| TT | Carrying two copies of the minor T allele is linked to the highest relative probability of reduced CETP expression among rs9923854 genotypes. This genotype has been enriched in certain long-lived European cohorts and is associated with modestly higher HDL cholesterol concentrations. | Favorable |
Genetic Location and the CETP Gene
The single nucleotide polymorphism rs9923854 sits upstream in the 5-prime flanking promoter region of the CETP gene, located on the long arm of chromosome 16 (16q13). CETP encodes cholesteryl ester transfer protein, a plasma lipid-transfer glycoprotein synthesized predominantly in the liver and adipose tissue. CETP facilitates the equimolar exchange of cholesteryl esters from atheroprotective high-density lipoproteins (HDL) to apolipoprotein B-containing particles, including very low-density lipoproteins (VLDL) and low-density lipoproteins (LDL). Because promoter variants can alter the binding affinity of transcriptional machinery or transcription factors, variations in this regulatory region can influence the baseline circulating concentration of the CETP enzyme. When CETP expression or activity is diminished, cholesterol clearance from HDL slows, frequently resulting in elevated levels of circulating HDL cholesterol and alterations in lipoprotein particle size.
Research on Longevity and Cognitive Health
Interest in CETP genetic variants accelerated following landmark studies of exceptionally long-lived cohorts, such as centenarians of Ashkenazi Jewish, Danish, and Dutch descent. Researchers observed that individuals carrying specific functional or promoter variants in CETP often exhibited higher circulating HDL cholesterol levels and larger lipoprotein particle sizes. In subsequent genetic association studies, the minor allele of rs9923854 has been evaluated as part of candidate gene screens for exceptional survival and cognitive resilience. Cohort analyses, including multi-center longevity evaluations across Northern European populations, identified statistically significant associations between rs9923854 and survival past the ninth and tenth decades of life. Furthermore, preserved scores on mini-mental cognitive evaluations were correlated with favorable lipoprotein profiles influenced by CETP variation. Nevertheless, the total biological effect size attributable to rs9923854 alone remains small, reflecting a modest contribution within a complex polygenic trait.
Strength of Evidence and Scientific Contradictions
The scientific evidence supporting a direct, causative link between rs9923854 and extended healthspan is categorized as limited. While candidate gene studies and regional European cohorts demonstrated nominal associations with longevity, replication attempts across diverse genetic backgrounds have yielded mixed results. For example, large-scale studies in Japanese, Italian, and Greek cohorts frequently observed no statistically significant survival advantage for specific CETP variants, or found borderline significance after stringent corrections for multiple testing. In addition, Mendelian randomization analyses evaluating lifelong CETP downregulation show complex outcomes: while lower CETP activity is broadly linked to elevated HDL and modest reductions in coronary artery disease risk, some studies report conflicting associations with age-related macular degeneration or neutral impacts on overall lifespan. Consequently, rs9923854 should be viewed as an interesting statistical biomarker in longevity research rather than a guaranteed determinant of healthspan.
Clinical Realities and Actionable Insights
Knowing your rs9923854 genotype provides interesting insight into your personal genome, but it cannot be used to diagnose any disease or accurately predict your eventual lifespan. Longevity and cognitive health are highly complex, polygenic phenotypes governed by thousands of subtle genetic variants interacting continuously with lifestyle, diet, exercise, and environmental exposures. Furthermore, pharmaceutical attempts to replicate genetic CETP deficiency using chemical CETP inhibitors have faced substantial clinical development hurdles, underscoring the nuance of lipid biology. Direct-to-consumer genetic findings should never prompt independent alterations to cardiovascular medications or statin regimens. If you have questions about your blood lipids, cardiovascular risk, or cognitive health, discuss your clinical lipid panels and comprehensive health history directly with your physician.
How common is this variant?
The minor allele (T) frequency for rs9923854 ranges between approximately 0.35 and 0.42 across European-descent populations. In non-European cohorts, including East Asian and African populations, the allele distribution varies widely and longevity associations are less consistently observed.
Frequently asked questions
What does having the favorable genotype for rs9923854 mean for my lifespan?
Carrying the minor allele of rs9923854 means your genetic profile matches a statistical pattern modestly enriched among certain long-lived European centenarians. However, it does not guarantee exceptional longevity or immunity from cardiovascular conditions. Lifespan is governed by thousands of genetic loci alongside dominant environmental and lifestyle factors.
Does rs9923854 directly affect my blood cholesterol tests?
Variants in the CETP promoter, including rs9923854, can influence the baseline rate at which your body transfers cholesterol between lipoprotein particles. While the minor allele is statistically correlated with slightly higher HDL cholesterol, diet, exercise, and other metabolic genes exert a far larger direct effect on your routine lipid panels.
Can rs9923854 protect me against dementia or memory loss?
Some observational studies noted that centenarians with favorable CETP variants preserved higher cognitive scores, likely mediated by vascular health and larger HDL particle sizes. However, rs9923854 does not confer complete protection against Alzheimer's disease or age-related cognitive decline, which remain multifaceted disorders.
Should I adjust my medications based on my CETP rs9923854 genotype?
No, you should never start, stop, or change any medication based on this genetic result. rs9923854 is an observational research marker and is not an approved pharmacogenetic guide for cardiovascular therapy. Any questions regarding cholesterol-lowering medications or overall cardiovascular risk should be discussed directly with a qualified healthcare provider.
Sources & further reading
Educational information only, last refreshed 9/10/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs9923854?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29